Close Menu

product launch

The gene expression test retrospectively identified rheumatoid arthritis patients significantly less likely to respond to TNF inhibitor therapy.

According to the company, the test has shown to be more sensitive and accurate than a COVID-19 anterior nasal swab test in the firm's EUA validation study.

The company recently presented results from its Aurora assay for multi-cancer screening and plans to launch a $100 test for the US and Chinese markets.

The Helsinki-based firm is making its panel available for free to people who already have been genotyped by consumer genomics services or biobanks.

The company's approach relies on an initial point-of-care lateral flow assay followed by a confirmatory real-time PCR analysis run in its laboratories.

Two recent acquisitions have resulted in the swift launch of two assays, one for the clinic and another for research use, as the firm's original test finally nears validation.

Founded by former Inteliquet CEO Carla Balch, the firm is building on visualization technology to help physicians incorporate MDx testing into their practice. 

The company announced the launch of the new products in the US and Europe as part of a product portfolio it has named Panther Scalable Solutions.

The diagnostic firms were the final companies in the coverage universe of 360Dx to present at the annual conference.

The Finnish biotechnology firm also announced plans to raise up to €80 million in the coming year.

Pages